Four-year data: On Wednesday, July 30, as part of the “Developing Topics Session: Innovative Therapeutic Approaches” (8:00 – 8:45 AM EDT ), initial four-year findings will be presented on lecanemab ...

Roche is focusing on early diagnosis of Alzheimer's disease and will soon release its first blood-based biomarker for the ...

Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation ...

ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.